Your browser doesn't support javascript.
loading
Immunogenicity of Calvenza-03 EIV/EHV® Vaccine in Horses: Comparative In Vivo Study.
Pavulraj, Selvaraj; Bergmann, Tobias; Trombetta, Claudia Maria; Marchi, Serena; Montomoli, Emanuele; Alami, Sidi Sefiane El; Ragni-Alunni, Roberto; Osterrieder, Nikolaus; Azab, Walid.
Afiliação
  • Pavulraj S; Institut für Virologie, Robert von Ostertag-Haus, Zentrum für Infektionsmedizin, Freie Universität Berlin, Robert-von-Ostertag-Str. 7-13, 14163 Berlin, Germany.
  • Bergmann T; Institut für Virologie, Robert von Ostertag-Haus, Zentrum für Infektionsmedizin, Freie Universität Berlin, Robert-von-Ostertag-Str. 7-13, 14163 Berlin, Germany.
  • Trombetta CM; Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.
  • Marchi S; Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.
  • Montomoli E; Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.
  • Alami SSE; VisMederi srl, 53100 Siena, Italy.
  • Ragni-Alunni R; AL-REEF Stable, Abu Dhabi P.O. Box 5151, United Arab Emirates.
  • Osterrieder N; Equine Marketing Division, Boehringer Ingelheim META, Dubai P.O. Box 507066, United Arab Emirates.
  • Azab W; Institut für Virologie, Robert von Ostertag-Haus, Zentrum für Infektionsmedizin, Freie Universität Berlin, Robert-von-Ostertag-Str. 7-13, 14163 Berlin, Germany.
Vaccines (Basel) ; 9(2)2021 Feb 17.
Article em En | MEDLINE | ID: mdl-33671378
Equine influenza (EI) is a highly contagious acute respiratory disease of equines that is caused mainly by the H3N8 subtype of influenza A virus. Vaccinating horses against EI is the most effective strategy to prevent the infection. The current study aimed to compare the kinetics of EI-specific humoral- and cell-mediated immunity (CMI) in horses receiving either identical or mixed vaccinations. Two groups of horses were previously (six months prior) vaccinated with either Calvenza 03 EIV EHV® (G1) or Fluvac Innovator® (G2) vaccine. Subsequently, both groups received a booster single dose of Calvenza 03 EIV EHV®. Immune responses were assessed after 10 weeks using single radial hemolysis (SRH), virus neutralization (VN), and EliSpot assays. Our results revealed that Calvenza-03 EIV/EHV®-immunized horses had significantly higher protective EI-specific SRH antibodies and VN antibodies. Booster immunization with Calvenza-03 EIV/EHV® vaccine significantly stimulated cell-mediated immune response as evidenced by significant increase in interferon-γ-secreting peripheral blood mononuclear cells. In conclusion, Calvenza-03 EIV/EHV® vaccine can be safely and effectively used for booster immunization to elicit optimal long persisting humoral and CMI responses even if the horses were previously immunized with a heterogeneous vaccine.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article